See more : Arcoma AB (ARCOMA.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Assertio Holdings, Inc. (ASRT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Assertio Holdings, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Winsan (Chengdu) Medical Science and Technology Co., Ltd. (600767.SS) Income Statement Analysis – Financial Results
- Blueprint Medicines Corporation (BPMC) Income Statement Analysis – Financial Results
- Transchem Limited (TRANSCHEM.BO) Income Statement Analysis – Financial Results
- Argus Capital Corp. (ARGUU) Income Statement Analysis – Financial Results
- Waterdrop Inc. (WDH) Income Statement Analysis – Financial Results
Assertio Holdings, Inc. (ASRT)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.assertiotx.com
About Assertio Holdings, Inc.
Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 152.07M | 156.23M | 111.01M | 106.28M | 229.50M | 311.77M | 380.72M | 455.90M | 342.74M | 390.36M | 134.21M | 90.82M | 132.97M | 80.76M | 57.73M | 34.84M | 65.58M | 9.55M | 4.41M | 202.57K | 981.99K | 1.66M | 3.67M | 1.78M | 115.33K | 800.00K | 600.00K | 300.00K |
| Cost of Revenue | 27.02M | 18.75M | 15.83M | 19.87M | 9.51M | 18.48M | 72.60M | 87.41M | 67.90M | 15.15M | 7.09M | 6.04M | 5.54M | 8.10M | 5.26M | 5.77M | 2.60M | 1.60M | 908.52K | 0.00 | 0.00 | 0.00 | 0.00 | -561.76K | -643.49K | -500.00K | -200.00K | 0.00 |
| Gross Profit | 125.05M | 137.49M | 95.18M | 86.40M | 220.00M | 293.29M | 308.13M | 368.48M | 274.84M | 375.22M | 127.11M | 84.78M | 127.43M | 72.67M | 52.47M | 29.07M | 62.99M | 7.95M | 3.50M | 202.57K | 981.99K | 1.66M | 3.67M | 2.34M | 758.82K | 1.30M | 800.00K | 300.00K |
| Gross Profit Ratio | 82.23% | 88.00% | 85.74% | 81.30% | 95.86% | 94.07% | 80.93% | 80.83% | 80.19% | 96.12% | 94.72% | 93.35% | 95.83% | 89.97% | 90.89% | 83.43% | 96.04% | 83.24% | 79.38% | 100.00% | 100.00% | 100.00% | 100.00% | 131.63% | 657.97% | 162.50% | 133.33% | 100.00% |
| Research & Development | 2.84M | 0.00 | 0.00 | 4.21M | 10.11M | 8.04M | 38.62M | 32.63M | 72.44M | 7.12M | 8.07M | 15.46M | 15.19M | 20.11M | 34.30M | 27.27M | 23.34M | 26.89M | 18.37M | 21.36M | 26.90M | 24.71M | 15.46M | 7.49M | 3.73M | 2.10M | 900.00K | 400.00K |
| General & Administrative | 65.34M | 43.39M | 54.76M | 103.92M | 108.07M | 118.42M | 192.00M | 200.40M | 197.05M | 119.33M | 105.18M | 97.65M | 54.21M | 17.51M | 16.66M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 4.40M | 3.40M | 1.80M | 400.00K | 800.00K | 800.00K | 3.70M | 4.10M | 2.30M | 1.80M | 2.40M | 1.50M | 27.34M | 31.42M | 23.59M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 78.64M | 46.79M | 56.56M | 104.32M | 108.87M | 119.22M | 195.70M | 204.50M | 199.35M | 121.13M | 105.18M | 97.65M | 81.54M | 48.93M | 40.25M | 26.40M | 26.69M | 22.67M | 11.64M | 5.18M | 3.48M | 5.37M | 2.53M | 2.03M | 1.87M | 2.00M | 1.00M | 400.00K |
| Other Expenses | 287.10M | 32.61M | 28.11M | 24.78M | 101.77M | 101.77M | 102.75M | 106.85M | 599.00K | 10.16M | -249.00K | 481.00K | 0.00 | 0.00 | 0.00 | -7.50M | -34.58M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 561.76K | 643.49K | 500.00K | 200.00K | 0.00 |
| Operating Expenses | 368.59M | 79.39M | 84.67M | 133.32M | 220.75M | 229.03M | 337.06M | 343.97M | 355.14M | 138.40M | 117.80M | 115.13M | 96.73M | 69.04M | 74.54M | 46.17M | 15.45M | 49.56M | 30.01M | 26.54M | 30.38M | 30.09M | 17.99M | 10.08M | 6.25M | 4.60M | 2.10M | 800.00K |
| Cost & Expenses | 395.61M | 98.14M | 100.50M | 153.19M | 230.25M | 247.51M | 409.66M | 431.39M | 423.04M | 153.55M | 124.89M | 121.17M | 102.28M | 77.14M | 79.80M | 51.94M | 18.04M | 51.16M | 30.92M | 26.54M | 30.38M | 30.09M | 17.99M | 9.51M | 5.61M | 4.10M | 1.90M | 800.00K |
| Interest Income | 0.00 | 7.96M | 10.22M | 15.93M | 58.39M | 1.20M | 681.00K | 485.00K | 599.00K | 215.00K | 662.00K | 520.00K | 557.00K | 839.00K | 1.05M | 2.35M | 2.27M | 2.03M | 1.45M | 489.01K | 299.14K | 101.11K | 0.00 | 222.95K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.38M | 7.96M | 10.22M | 15.93M | 58.39M | 68.88M | 73.55M | 83.72M | 73.44M | 23.92M | 4.49M | 39.00K | 133.00K | 572.00K | 1.00M | 555.00K | 0.00 | 0.00 | 459.74K | 928.88K | 910.42K | 732.57K | 105.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 28.23M | 33.41M | 29.11M | 26.38M | 102.97M | 106.43M | 105.50M | 109.38M | 83.34M | 10.16M | 4.55M | 2.02M | 420.00K | 439.00K | 808.00K | 1.15M | 865.00K | 1.38M | 1.14M | 1.70M | 1.04M | 745.14K | 610.81K | 561.76K | 643.49K | 500.00K | 200.00K | 0.00 |
| EBITDA | -222.45M | 72.54M | 38.78M | -3.20M | -61.12M | 213.16M | 74.05M | 133.76M | 35.94M | 252.64M | 16.68M | -27.27M | 71.68M | 4.90M | -20.21M | -13.60M | 48.40M | -40.23M | -25.37M | -24.63M | -28.35M | -27.68M | -13.71M | -7.18M | -4.85M | -2.84M | -1.00M | -500.00K |
| EBITDA Ratio | -146.28% | 58.38% | 35.88% | -23.86% | 45.74% | 53.64% | 19.57% | 28.92% | 1.06% | 63.32% | 10.15% | -31.20% | -7.00% | 5.53% | -36.42% | -67.30% | 21.07% | -421.17% | -599.99% | -12,160.55% | -2,887.38% | -2,749.98% | -373.25% | -280.87% | 6,215.39% | -412.50% | -183.33% | -166.67% |
| Operating Income | -243.54M | 57.81M | 9.42M | -46.92M | 3.20M | 43.66M | -42.18M | 24.51M | -50.40M | 236.81M | 9.32M | -30.35M | 70.70M | 3.63M | -22.07M | -17.10M | 47.54M | -41.61M | -26.51M | -26.33M | -29.40M | -28.43M | -14.32M | -7.74M | -5.49M | -3.30M | -1.30M | -500.00K |
| Operating Income Ratio | -160.15% | 37.00% | 8.49% | -44.15% | 1.39% | 14.00% | -11.08% | 5.38% | -14.71% | 60.67% | 6.94% | -33.42% | 53.17% | 4.49% | -38.23% | -49.06% | 72.49% | -435.62% | -601.81% | -13,000.40% | -2,993.76% | -1,711.27% | -389.88% | -435.66% | -4,760.78% | -412.50% | -216.67% | -166.67% |
| Total Other Income/Expenses | -10.52M | -26.65M | -9.98M | 36.64M | -28.06M | -5.68M | -61.75M | -89.01M | -72.84M | -23.71M | -4.74M | 481.00K | 424.00K | 267.00K | 49.00K | 1.79M | 39.56M | 2.03M | 2.04M | -439.87K | -5.36K | 15.56M | -3.17M | -2.19M | -12.02M | 536.86K | 0.00 | 500.00K |
| Income Before Tax | -254.05M | 31.17M | -553.00K | -45.51M | -222.48M | 37.98M | -103.92M | -64.50M | -123.24M | 213.11M | 4.58M | -29.87M | 71.12M | 3.89M | -22.02M | -15.30M | 49.81M | -39.58M | -24.47M | -26.77M | -29.40M | -12.86M | -17.49M | -9.93M | -17.51M | -2.80M | 0.00 | 0.00 |
| Income Before Tax Ratio | -167.06% | 19.95% | -0.50% | -42.83% | -96.94% | 12.18% | -27.30% | -14.15% | -35.96% | 54.59% | 3.41% | -32.89% | 53.49% | 4.82% | -38.15% | -43.92% | 75.95% | -414.36% | -555.40% | -13,217.54% | -2,994.31% | -774.33% | -476.27% | -558.82% | -15,178.98% | -350.00% | 0.00% | 0.00% |
| Income Tax Expense | 77.89M | -78.46M | 728.00K | -17.37M | -5.28M | 1.07M | -1.43M | 24.22M | -47.50M | 81.35M | -38.73M | -91.00K | 396.00K | -4.00K | -15.00K | 1.00K | 592.00K | 82.50K | -2.04M | 99.00K | 611.28K | -17.37M | 105.20K | 1.96M | 11.72M | -500.00K | -100.00K | 500.00K |
| Net Income | -331.94M | 109.63M | -1.28M | -28.14M | -217.20M | 36.91M | -102.50M | -88.72M | -75.74M | 131.76M | 43.31M | -29.78M | 70.73M | 3.90M | -22.01M | -15.30M | 49.22M | -39.66M | -24.47M | -26.87M | -30.02M | -13.49M | -17.60M | -9.70M | -17.21M | -2.80M | -1.20M | -500.00K |
| Net Income Ratio | -218.28% | 70.17% | -1.15% | -26.48% | -94.64% | 11.84% | -26.92% | -19.46% | -22.10% | 33.75% | 32.27% | -32.79% | 53.19% | 4.82% | -38.12% | -43.92% | 75.05% | -415.23% | -555.40% | -13,266.41% | -3,056.56% | -812.35% | -479.13% | -546.27% | -14,921.74% | -350.00% | -200.00% | -166.67% |
| EPS | -4.67 | 2.33 | -0.03 | -1.07 | -12.29 | 2.31 | -6.54 | -5.80 | -5.04 | 9.04 | 3.04 | -2.13 | 5.20 | 0.28 | -1.71 | -1.25 | 4.24 | -3.82 | -2.46 | -3.10 | -4.91 | -3.69 | -6.89 | -5.29 | -10.63 | -1.77 | -1.08 | -0.48 |
| EPS Diluted | -4.67 | 2.01 | -0.03 | -1.07 | -12.29 | 2.30 | -6.54 | -5.79 | -5.04 | 8.20 | 3.00 | -2.13 | 5.04 | 0.28 | -1.71 | -1.25 | 4.20 | -3.82 | -2.46 | -3.10 | -4.91 | -3.69 | -6.89 | -5.29 | -10.63 | -1.77 | -1.08 | -0.48 |
| Weighted Avg Shares Out | 71.03M | 47.00M | 43.17M | 26.21M | 17.68M | 15.95M | 15.68M | 15.30M | 15.03M | 14.57M | 14.18M | 13.97M | 13.64M | 13.13M | 12.88M | 12.19M | 11.49M | 10.38M | 9.96M | 8.66M | 6.11M | 3.66M | 2.56M | 1.83M | 1.62M | 1.58M | 1.11M | 1.04M |
| Weighted Avg Shares Out (Dil) | 71.03M | 54.67M | 43.17M | 26.21M | 17.68M | 16.05M | 15.68M | 15.32M | 15.03M | 16.58M | 14.39M | 13.97M | 14.02M | 13.34M | 12.88M | 12.19M | 11.59M | 10.38M | 9.96M | 8.66M | 6.11M | 3.66M | 2.56M | 1.83M | 1.62M | 1.58M | 1.11M | 1.04M |
Assertio Holdings: Management Change Could Improve Comeback Chances
After losing exclusivity with its prior flagship drug, pharma firm Assertio Holdings (ASRT) is angling for a comeback with a new flagship drug product. However, Assertio's latest fiscal results were mixed at best, suggesting challenges ahead with its turnaround efforts....
Assertio to Participate in the HC Wainwright and Lake Street Conferences in New York City September 10-12, 2024
LAKE FOREST, Ill., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that Ajay Patel, Chief Financial Officer, will host investor...
Assertio Holdings, Inc. (ASRT) Q2 2024 Earnings Call Transcript
Assertio Holdings, Inc. (NASDAQ:ASRT ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Matthew Kreps - Darrow Associates, IR Brendan O'Grady - Chief Executive Officer Ajay Patel - Senior Vice President and Chief Financial Officer...
Assertio (ASRT) Reports Q2 Loss, Tops Revenue Estimates
Assertio (ASRT) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.13 per share a year ago.
Assertio Reports Second Quarter 2024 Financial Results
Second Quarter Total Net Product Sales of $30.7 Million Rolvedon Growth Continues, with $15.1 million in Net Product Sales $7.4 Million in Cash Flow from Operations, Cash and Short-Term Investments Increases to $88.4 Million LAKE FOREST, Ill., Aug. 07, 2024...
Earnings Preview: Assertio (ASRT) Q2 Earnings Expected to Decline
Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Assertio Holdings, Inc. to Report Second Quarter 2024 Financial Results on August 7, 2024
LAKE FOREST, Ill., July 24, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that it will release second quarter 2024 financial...
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
LAKE FOREST, Ill., July 09, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that effective July 1, 2024, the Compensation Committee of...
ASSERTIO ALERT: Bragar Eagel & Squire, P.C. is Investigating Assertio Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Assertio Holdings, Inc. (NASDAQ: ASRT) on behalf of long-term stockholders following a class action complaint...
Assertio: An Extremely Asymmetric Bet Skewed To The Upside
Assertio Holdings, Inc. shares present a significant upside potential due to ongoing turnaround efforts and proven success in monetizing underappreciated pharma assets. The merger with Spectrum Pharmaceuticals saved Assertio from potential collapse after a generic drug approval, providing a new...
Source: https://incomestatements.info
Category: Stock Reports